Abiopharma

New Form 8-K - Incannex Healthcare Inc. Filed: 2025-08-08 AccNo: 0001213900-25-073321 Size: 383 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form DEF 14A - XWELL, Inc. Filed: 2025-08-08 AccNo: 0001104659-25-075469 Size: 2 MB

New Form DEF 14A - BullFrog AI Holdings, Inc. Filed: 2025-08-08 AccNo: 0001641172-25-022671 Size: 344 KB

New Form 6-K - Quantum Biopharma Ltd. Filed: 2025-08-08 AccNo: 0001171843-25-005204 Size: 14 KB

Quantum-Si to Participate in the UBS Precision Medicine Frontiers Summit

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

New Form SCHEDULE 13D/A - STAAR SURGICAL CO Filed: 2025-08-08 AccNo: 0000919574-25-004394 Size: 22 KB

New Form 10-Q - SURMODICS INC Filed: 2025-08-08 AccNo: 0000950170-25-105477 Size: 10 MB

Spectral Medical Announces Second Quarter and Provides Corporate Update

New Form 8-K - HAWKINS INC Filed: 2025-08-08 AccNo: 0000046250-25-000048 Size: 566 KB Item 7.01: Regulation FD Disclosure

New Form 10-Q - HERON THERAPEUTICS, INC. /DE/ Filed: 2025-08-08 AccNo: 0000950170-25-105475 Size: 9 MB

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress